Folic Acid side effects: what 247,820 FDA adverse event reports show
Drug class
Not stated in label
Who reports
247,820 reports · 74% serious · 23,149 with death outcome · 68% female
Used for
Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood.
What it is
Folic acid is an N-acyl-amino acid that is a form of the water-soluble vitamin B9. Its biologically active forms (tetrahydrofolate and others) are essential for nucleotide biosynthesis and homocysteine remethylation.
Boxed warning
None in the current label
Causality screen of the 40 strongest signals
What the badges mean
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,151 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Anti-cyclic citrullinated peptide antibody positive | 5,560 | 315.2 297.5–333.9ROR 322.4 · calibrated p 5e-12 ✓ | 66.2 EB05 64.7 · IC025 +6.0 3/3 methods agree | Lab value / disease marker | serious PRR 51.5 · ♀ 100% (drug 68%) · 93% clinician | not reported in cached trials |
| Anti-cyclic citrullinated peptide antibody | 497 | 253.0 211.9–302.1ROR 253.5 · calibrated p 6e-11 ✓ | 62.8 EB05 58.3 · IC025 +5.7 3/3 methods agree | Lab value / disease marker | serious n=497 · ♀ 100% (drug 68%) · 100% clinician | not reported in cached trials |
| Swollen joint count increased | 2,292 | 240.2 221.5–260.4ROR 242.4 · calibrated p 7e-11 ✓ | 62.1 EB05 60.0 · IC025 +5.9 3/3 methods agree | Lab value / disease marker | serious n=2,290 · ♀ 100% (drug 68%) · 95% clinician | not reported in cached trials |
| Pemphigus | 9,103 | 237.1 227.7–246.8ROR 246.1 · calibrated p 6e-11 ✓ | 61.9 EB05 60.9 · IC025 +5.9 3/3 methods agree | Not in label — unassessed | serious PRR 48.2 · ♀ 100% (drug 68%) | not reported in cached trials |
| Rheumatic fever | 3,085 | 207.4 194.1–221.5ROR 210.0 · calibrated p 3e-10 ✓ | 59.7 EB05 58.0 · IC025 +5.8 3/3 methods agree | Not in label — unassessed | serious n=3,084 · ♀ 100% (drug 68%) · 94% clinician | not reported in cached trials |
| Deep vein thrombosis postoperative | 1,349 | 189.6 172.1–208.8ROR 190.6 · calibrated p 6e-10 ✓ | 58.1 EB05 55.6 · IC025 +5.7 3/3 methods agree | Not in label — unassessed | serious n=1,349 · ♀ 100% (drug 68%) · 93% clinician | not reported in cached trials |
| Duodenal ulcer perforation | 5,016 | 185.5 176.5–195.0ROR 189.3 · calibrated p 6e-10 ✓ | 57.8 EB05 56.4 · IC025 +5.8 3/3 methods agree | Not in label — unassessed | serious PRR 44.8 · ♀ 100% (drug 68%) · 93% clinician | not reported in cached trials |
| Rheumatoid factor positive | 3,719 | 155.2 147.0–163.9ROR 157.6 · calibrated p 3e-9 ✓ | 54.5 EB05 53.0 · IC025 +5.7 3/3 methods agree | Lab value / disease marker | serious n=3,716 · ♀ 100% (drug 68%) · 94% clinician | not reported in cached trials |
| Lupus vulgaris | 756 | 148.8 132.1–167.7ROR 149.3 · calibrated p 5e-9 ✓ | 53.6 EB05 50.5 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | serious n=756 · ♀ 100% (drug 68%) · 100% clinician | not reported in cached trials |
| C-reactive protein | 575 | 147.7 128.9–169.4ROR 148.1 · calibrated p 6e-9 ✓ | 53.5 EB05 49.9 · IC025 +5.5 3/3 methods agree | Lab value / disease marker | serious n=574 · ♀ 100% (drug 68%) · 100% clinician | not reported in cached trials |
| Hand deformity | 7,652 | 120.0 115.9–124.2ROR 123.8 · calibrated p 2e-8 ✓ | 49.5 EB05 48.5 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | serious PRR 41.5 · ♀ 98% (drug 68%) | not reported in cached trials |
| Facet joint syndrome | 1,834 | 118.4 110.2–127.1ROR 119.2 · calibrated p 3e-8 ✓ | 49.2 EB05 47.3 · IC025 +5.5 3/3 methods agree | Not in label — unassessed | serious n=1,831 · ♀ 100% (drug 68%) · 94% clinician | not reported in cached trials |
| Adjustment disorder with depressed mood | 1,009 | 84.8 77.7–92.6ROR 85.2 · calibrated p 4e-7 ✓ | 42.3 EB05 40.2 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious n=1,007 · ♀ 100% (drug 68%) · 100% clinician | not reported in cached trials |
| Helicobacter infection | 5,026 | 82.3 79.2–85.6ROR 84.0 · calibrated p 4e-7 ✓ | 41.7 EB05 40.7 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious PRR 34.1 · ♀ 100% (drug 68%) · 93% clinician | not reported in cached trials |
| Dislocation of vertebra | 1,022 | 71.8 66.0–78.1ROR 72.1 · calibrated p 1e-6 ✓ | 38.8 EB05 36.9 · IC025 +5.2 3/3 methods agree | Not in label — unassessed | serious n=1,022 · ♀ 100% (drug 68%) · 93% clinician | not reported in cached trials |
| X-ray abnormal | 778 | 65.2 59.4–71.6ROR 65.4 · calibrated p 2e-6 ✓ | 36.8 EB05 34.7 · IC025 +5.1 3/3 methods agree | Lab value / disease marker | serious n=778 · ♀ 100% (drug 68%) · 100% clinician | not reported in cached trials |
| Synovitis | 7,632 | 61.8 60.0–63.7ROR 63.8 · calibrated p 3e-6 ✓ | 35.8 EB05 35.1 · IC025 +5.1 3/3 methods agree | Not in label — unassessed | serious PRR 29.0 · ♀ 95% (drug 68%) | not reported in cached trials |
| Muscle injury | 3,461 | 61.5 58.9–64.3ROR 62.4 · calibrated p 3e-6 ✓ | 35.7 EB05 34.7 · IC025 +5.1 3/3 methods agree | Not in label — unassessed | serious PRR 29.9 · ♀ 100% (drug 68%) · 94% clinician | not reported in cached trials |
| C-reactive protein abnormal | 2,657 | 59.8 56.9–62.8ROR 60.4 · calibrated p 4e-6 ✓ | 35.1 EB05 34.0 · IC025 +5.1 3/3 methods agree | Lab value / disease marker | serious n=2,656 · ♀ 92% (drug 68%) · 90% clinician | not reported in cached trials |
| Sleep disorder due to general medical condition, insomnia type | 2,604 | 57.3 54.5–60.2ROR 57.9 · calibrated p 5e-6 ✓ | 34.2 EB05 33.1 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious n=2,594 · ♀ 100% (drug 68%) · 94% clinician | not reported in cached trials |
| Retinitis | 646 | 53.2 48.2–58.7ROR 53.3 · calibrated p 9e-6 ✓ | 32.7 EB05 30.6 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious n=645 · ♀ 100% (drug 68%) · 100% clinician | not reported in cached trials |
| Folliculitis | 3,968 | 52.6 50.5–54.7ROR 53.4 · calibrated p 9e-6 ✓ | 32.5 EB05 31.6 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious PRR 29.6 · ♀ 100% (drug 68%) · 94% clinician | not reported in cached trials |
| Glossodynia (burning tongue/mouth pain) | 8,543 | 52.1 50.7–53.5ROR 53.9 · calibrated p 8e-6 ✓ | 32.3 EB05 31.7 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious PRR 36.0 · ♀ 100% (drug 68%) | not reported in cached trials |
| Pericarditis | 6,204 | 50.0 48.4–51.5ROR 51.2 · calibrated p 1e-5 ✓ | 31.5 EB05 30.8 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious PRR 24.6 · ♀ 98% (drug 68%) · 93% clinician | not reported in cached trials |
| Peripheral venous disease | 1,423 | 46.6 43.7–49.7ROR 46.9 · calibrated p 2e-5 ✓ | 30.1 EB05 28.8 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious n=1,417 · ♀ 100% (drug 68%) · 91% clinician | not reported in cached trials |
| Subcutaneous drug absorption impaired | 194 | 46.5 39.0–55.5ROR 46.6 · calibrated p 2e-5 ✓ | 30.0 EB05 26.6 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=193 · ♀ 100% (drug 68%) · 100% clinician | not reported in cached trials |
| Blood pressure systolic abnormal | 845 | 43.2 39.8–47.0ROR 43.4 · calibrated p 3e-5 ✓ | 28.7 EB05 27.1 · IC025 +4.7 3/3 methods agree | Lab value / disease marker | serious n=828 | not reported in cached trials |
| Blood pressure diastolic abnormal | 853 | 41.8 38.5–45.4ROR 41.9 · calibrated p 4e-5 ✓ | 28.1 EB05 26.5 · IC025 +4.7 3/3 methods agree | Lab value / disease marker | serious n=832 | not reported in cached trials |
| Red blood cell sedimentation rate abnormal | 751 | 40.1 36.7–43.7ROR 40.2 · calibrated p 5e-5 ✓ | 27.3 EB05 25.7 · IC025 +4.6 3/3 methods agree | Lab value / disease marker | serious n=747 · ♀ 92% (drug 68%) | not reported in cached trials |
| Seronegative arthritis | 345 | 37.3 32.8–42.3ROR 37.3 · calibrated p 8e-5 ✓ | 26.0 EB05 23.7 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=342 · ♀ 100% (drug 68%) · 100% clinician | not reported in cached trials |
| Bone erosion | 1,021 | 34.0 31.6–36.6ROR 34.1 · calibrated p 1e-4 ✓ | 24.4 EB05 23.1 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=1,018 · ♀ 93% (drug 68%) | not reported in cached trials |
| Systemic lupus erythematosus | 10,175 | 33.9 33.2–34.7ROR 35.3 · calibrated p 1e-4 ✓ | 24.3 EB05 23.9 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | age-adj. PRR 26.7 · serious PRR 19.3 · ♀ 98% (drug 68%) | not reported in cached trials |
| Wound | 7,529 | 31.2 30.4–32.0ROR 32.1 · calibrated p 2e-4 ✓ | 22.9 EB05 22.5 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | age-adj. PRR 22.3 · serious PRR 20.9 · ♀ 96% (drug 68%) | not reported in cached trials |
| Granuloma skin | 212 | 28.9 24.7–33.7ROR 28.9 · calibrated p 3e-4 ✓ | 21.6 EB05 19.3 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=209 · ♀ 100% (drug 68%) · 100% clinician | not reported in cached trials |
| Contraindicated product administered | 7,310 | 26.8 26.2–27.6ROR 27.6 · calibrated p 4e-4 ✓ | 20.5 EB05 20.1 · IC025 +4.3 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 19.4 · serious PRR 19.7 · ♀ 97% (drug 68%) | not reported in cached trials |
| Joint destruction | 362 | 25.3 22.5–28.4ROR 25.3 · calibrated p 7e-4 ✓ | 19.6 EB05 17.9 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=358 · ♀ 100% (drug 68%) · 100% clinician | not reported in cached trials |
| Enthesopathy | 356 | 24.4 21.7–27.5ROR 24.5 · calibrated p 8e-4 ✓ | 19.1 EB05 17.5 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=352 · 100% clinician | not reported in cached trials |
| Breast cancer stage iii | 1,443 | 24.3 22.9–25.7ROR 24.4 · calibrated p 8e-4 ✓ | 19.0 EB05 18.2 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=1,443 · ♀ 100% (drug 68%) · 94% clinician | not reported in cached trials |
| Drug tolerance decreased | 618 | 23.8 21.7–26.0ROR 23.8 · calibrated p 9e-4 ✓ | 18.7 EB05 17.5 · IC025 +4.1 3/3 methods agree | Labeled (related wording) related wording | serious n=611 · ♀ 100% (drug 68%) · 100% clinician | not reported in cached trials |
| Grip strength decreased | 1,870 | 22.8 21.7–24.0ROR 23.0 · calibrated p 0.001 ✓ | 18.1 EB05 17.4 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=1,822 · ♀ 93% (drug 68%) | not reported in cached trials |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Liver injury | 12,583 | 3.63.6–3.7 | signal |
| Interstitial lung disease | 3,873 | 3.53.4–3.6 | signal |
| Serious infection | 25,806 | 2.92.9–2.9 | signal |
| Anaemia | 9,979 | 2.92.8–2.9 | signal |
| Tendon disorder | 1,221 | 2.82.6–2.9 | signal |
| Opportunistic infection | 3,878 | 2.42.4–2.5 | signal |
| Fall / fracture | 9,896 | 2.22.2–2.3 | signal |
| Thrombocytopenia | 4,850 | 1.91.8–1.9 | raised |
| Gi bleeding | 3,900 | 1.81.8–1.9 | raised |
| Hyperglycaemia / diabetes | 7,321 | 1.81.8–1.8 | raised |
| Hyponatraemia | 1,687 | 1.81.7–1.9 | raised |
| Depression | 5,746 | 1.71.7–1.8 | raised |
| Venous thromboembolism | 4,155 | 1.61.6–1.7 | raised |
| Kidney injury | 8,431 | 1.61.5–1.6 | raised |
| Pancreatitis | 1,387 | 1.51.4–1.5 | raised |
| Neutropenia / agranulocytosis | 4,235 | 1.51.4–1.5 | raised |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Folic Acid as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (0 of 40 signal terms matched).
- NCT00124072 — Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (N=12064, PHASE3; 5 AE terms posted; arms: Simvastatin 20 mg Daily; Simvastatin 80 mg Daily; Folic Acid 2 mg + Vitamin B12 1 mg Daily; Placebo)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug ineffective (drug did not work) | 25,266 | 1.6 1.6–1.7ROR 1.7 · calibrated p 0.774 | 1.6 EB05 1.6 · IC025 +0.7 | Reporting / coding artifact | age-adj. PRR 1.8 · serious PRR 2.8 | not reported in cached trials |
| Fatigue (tiredness) | 23,919 | 2.7 2.6–2.7ROR 2.8 · calibrated p 0.683 | 2.6 EB05 2.6 · IC025 +1.4 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.2 · serious PRR 3.1 | not reported in cached trials |
| Pain | 23,617 | 3.3 3.3–3.4ROR 3.6 · calibrated p 0.464 | 3.2 EB05 3.2 · IC025 +1.7 3/3 methods agree | Not in label — unassessed | age-adj. PRR 3.1 · serious PRR 3.4 | NCT00124072: 156/6,033 (2.6%) on Folic Acid; 154/6,031 (2.6%) control |
| Arthralgia (joint pain) | 19,991 | 4.2 4.2–4.3ROR 4.5 · calibrated p 0.293 | 4.1 EB05 4.0 · IC025 +2.0 3/3 methods agree | Not in label — unassessed | age-adj. PRR 3.7 · serious PRR 4.8 | not reported in cached trials |
| Off label use (used outside approved label) | 18,070 | 1.8 1.8–1.8ROR 1.8 · calibrated p 0.853 | 1.8 EB05 1.7 · IC025 +0.8 | Reporting / coding artifact | age-adj. PRR 1.7 · serious PRR 2.2 | not reported in cached trials |
| Rheumatoid arthritis | 17,937 | 15.8 15.6–16.0ROR 17.0 · calibrated p 0.004 ✓ | 13.4 EB05 13.3 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | age-adj. PRR 12.9 · serious PRR 11.9 · ♀ 89% (drug 68%) | not reported in cached trials |
| Nausea | 16,044 | 1.7 1.7–1.8ROR 1.8 · calibrated p 0.822 | 1.7 EB05 1.7 · IC025 +0.8 | Labeled adverse reaction exact term | age-adj. PRR 1.6 · serious PRR 2.0 | not reported in cached trials |
| Headache | 14,600 | 2.0 2.0–2.0ROR 2.1 · calibrated p 0.976 | 2.0 EB05 1.9 · IC025 +1.0 | Not in label — unassessed | age-adj. PRR 1.8 · serious PRR 2.4 | not reported in cached trials |
| Diarrhoea (diarrhea) | 14,599 | 1.9 1.9–2.0ROR 2.0 · calibrated p 0.944 | 1.9 EB05 1.9 · IC025 +0.9 | Not in label — unassessed | age-adj. PRR 1.8 · serious PRR 2.0 | not reported in cached trials |
| Rash | 14,022 | 2.8 2.7–2.8ROR 2.9 · calibrated p 0.659 | 2.7 EB05 2.7 · IC025 +1.4 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.5 · serious PRR 4.0 | not reported in cached trials |
| Dyspnoea (shortness of breath) | 13,655 | 2.1 2.0–2.1ROR 2.1 · calibrated p 0.986 | 2.0 EB05 2.0 · IC025 +1.0 3/3 methods agree | Not in label — unassessed | age-adj. PRR 1.8 · serious PRR 2.0 | not reported in cached trials |
| Abdominal discomfort | 11,979 | 6.5 6.3–6.6ROR 6.7 · calibrated p 0.110 | 6.1 EB05 6.0 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | age-adj. PRR 4.8 · serious PRR 9.8 · ♀ 91% (drug 68%) | not reported in cached trials |
| Alopecia (hair loss) | 11,928 | 5.4 5.3–5.5ROR 5.6 · calibrated p 0.177 | 5.1 EB05 5.1 · IC025 +2.3 3/3 methods agree | Not in label — unassessed | age-adj. PRR 3.9 · serious PRR 7.8 · ♀ 98% (drug 68%) | not reported in cached trials |
| Joint swelling | 11,794 | 9.1 8.9–9.3ROR 9.5 · calibrated p 0.038 ✓ | 8.3 EB05 8.2 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | age-adj. PRR 7.5 · serious PRR 10.1 · ♀ 89% (drug 68%) | not reported in cached trials |
| Condition aggravated | 11,481 | 3.3 3.2–3.4ROR 3.4 · calibrated p 0.505 | 3.2 EB05 3.2 · IC025 +1.7 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 3.0 · serious PRR 3.5 | not reported in cached trials |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Pemphigus — n=9,103, PRR 237.1
- Rheumatic fever — n=3,085, PRR 207.4
- Deep vein thrombosis postoperative — n=1,349, PRR 189.6
- Duodenal ulcer perforation — n=5,016, PRR 185.5
- Lupus vulgaris — n=756, PRR 148.8
- Hand deformity — n=7,652, PRR 120.0
- Facet joint syndrome — n=1,834, PRR 118.4
- Adjustment disorder with depressed mood — n=1,009, PRR 84.8
- Helicobacter infection — n=5,026, PRR 82.3
- Dislocation of vertebra — n=1,022, PRR 71.8
✓ A hand-written Bradford Hill causality assessment exists for this drug: Zoledronic acid (bisphosphonates) ↔ Osteonecrosis of the jaw.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Folic Acid?
In FDA FAERS, the most frequently co-reported reaction terms for Folic Acid are fatigue, pain, arthralgia, rheumatoid arthritis, nausea, headache. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Folic Acid have an FDA boxed warning?
No. The FDA label retrieved for Folic Acid has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Folic Acid causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 0b263a1e-260b-4775-a76e-766add336f12, effective 20231204; matched on
openfda.generic_name.exact:"FOLIC ACID" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - PubChem CID 135398658 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,191 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
FOLIC ACID, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.